Experience with low-dose oestrogen in the treatment of advanced prostate cancer: A personal view

British Journal of Urology

Volumn 78, Issue 6, 1996, Pages 921-928

  Bishop, M C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Advanced prostate cancer; Low dose hormone therapy; Oestrogen

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; DIETHYLSTILBESTROL; ESTROGEN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; EDEMA; GYNECOMASTIA; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; DIETHYLSTILBESTROL; DISEASE PROGRESSION; EDEMA; GYNECOMASTIA; HUMANS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TESTOSTERONE;

EID: 0030429869     PISSN: 00071331     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410x.1996.23320.x     Document Type: Article

References (16)

1. Byar DP. The Veterans Administration Co-operative Urological Research Groups studies of cancer of the prostate. Cancer 1973: 32: 1126-30
2. Shearer RJ, Hendry WF, Somerville IF et al. Plasma testosterone: an accurate monitor of hormone treatment in prostate cancer. Br J Urol 1973: 45: 668-72
3. Kent JR, Bishoff AJ. Arduino LJ et al. Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. J Urol 1973; 109: 858-60
4. Robinson MRG, Smith PH, Richards B, Newling DWW. de Pauw M. Sylvester R. The final analysis of the EORTC genito-urinary tract cancer co-operative group phase III clinical trial (protocol 30805) comparing orchidectomy plus Cyproterone acetate and low dose Stilboestrol in the management of metastatic carcinoma of the prostate. Eur Urol 1995: 28: 272-83
5. Prostate Cancer Trialists' Collaborative Group. Maximal androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995: 346: 265-9
6. Denis LJ. Whelan P. Carnero de Maura JL et al. Goserelin acetate and flutamide versus bilateral orchidectomy; a phase EORTC trial (30853). Urology 1993; 42: 119-30
7. Bishop MC, Lemberger RJ. Selby C. Lawrence WT. Oestrogen dosage in prostatic cancer: the threshold effect? Br J Urol 1989: 64: 290-6
8. Trachtenberg J. Optimal testosterone concentrations for the treatment of prostatic cancer. J Urol 1985:133: 888-91
9. Kontturi M. Metabolic side effects of estrogen therapy for prostatic cancer. Scand }Urol Nephrol Suppl. 1991: 138: 127-30
10. Antiplatelet trialists collaboration. Collaborative overview of randomised trials of antiplatelet therapy III. Reduction in venous thrombosis and pulmonary embolism and antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994: 308: 235-46
11. Donati MB. Cancer and thrombosis. Haemostasis 1994; 24: 128-31
12. Kakkur AK. De Ruvo N, Chinswangwatanakul V. Tebbutl S, Williamson RCN. Extrinsic pathway activation in cancer with high factor Vila and tissue factor. Lancet 1995; 346: 1004-5
13. Seal US. Doe RP. Byar DP et al Response of plasma librinogen and plasminogen to hormonal treatment and the relation of pre-treatment values to mortality in patients with proslatic cancer. Cancer 1976; 38: 1108-17
14. Vahlensieck W. Wagner G. Continuous versus intermittent oral therapy with Estramustine phosphate (Estracyt). Scaud J Uwl Seplmil 1980; 55 (suppl): 147-9
15. Klotz, LH. Herr HW. Morse MJ et ni. Intermittent endocrine therapy for advanced prostatic cancer. Cancer 1986; 58: 2546-50
16. Goldenberg SL. Bruchovsky N. Cleave ME, Sullivan LD, Koichiro A. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urolocifi 1995: 45: 839-45